Use of gemifloxacin compounds, which can be active against bacterial strains resistant to other antibiotics, in treatment of infections caused by respiratory tract pathogenic bacteria

摘要

Gemifloxacin compounds are used to modulate the metabolism of respiratory tract pathogenic bacteria, and to treat and prevent infection by such bacteria. Independent claims are included for: (1) modulating metabolism of respiratory tract pathogenic bacteria, comprising contacting the bacteria with a composition comprising a gemifloxacin compound, or derivative of this; and (2) treating or preventing infection by respiratory tract pathogenic bacteria, comprising administering a gemifloxacin compound to a mammal. ACTIVITY : Antibacterial. In tests, gemifloxacin exhibited activity against S. pneumoniae, with MIC90 values of 0.03 Microg/ml for both penicillin-susceptible and penicillin-resistant strains. It was active against S. aureus, with MIC90 values of 0.03 Microg/ml for methicillin-resistant strains. It was active against all isolates of H. influenzae and M. catarrhalis tested, with MIC90 values of 0.008 Microg/ml for at least some of these. MECHANISM OF ACTION : None given.